ArticleActa neurologica Belgica2026
Cerebral microbleeds aggravate severity of motor function, cognitive and emotional status in Parkinson's disease.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCerebral microbleeds (CMBs) are highly prevalent in patients with Parkinson's disease (PD), but their impact on clinical symptom severity and genetic association remains unclear. This study investigates the relationship between CMBs and PD severity.
methodsWe recruited patients with PD from the outpatient clinic and inpatient wards of the First Affiliated Hospital of Chongqing Medical University. All participants had undergone susceptibility-weighted imaging (SWI) and had complete clinical assessments. Participants were categorized into groups based on their CMB count. We subsequently analyzed the risk factors for CMBs and examined the correlations between CMB burden and motor, cognitive, and emotional function, respectively. Furthermore, utilizing a genome-wide association study (GWAS) dataset, we investigated the association between genetic susceptibility to CMBs and PD severity preliminarily by Mendelian randomization (MR).
resultsAmong 158 patients with PD, 53 (33.5%) were found to have CMBs. Age, disease duration, and hypertension were independently associated with the presence of CMBs (p < 0.05). Multiple linear regression analysis indicated that a higher CMB burden was associated with poorer motor function and the presence of anxiety disorders. To gain deeper insight into the relationship between CMB and severity of PD, MR analysis further suggested that genetic susceptibility to CMBs is potentially causally linked to worse motor function (OR = 1.301, p = 0.047), lower scores on the Montreal Cognitive Assessment (MoCA) (OR = 0.207, p = 0.021) and the Mini-Mental State Examination (MMSE) (OR = 4.915, p = 1.63E-08), as well as an increased risk of dementia in PD (OR = 4.915, p = 1.63E-08).
conclusionThe high prevalence of CMBs was associated with age, disease duration, and hypertension. Furthermore, our MR analysis provides preliminary evidence that a higher CMB burden may exacerbate the severity of Parkinson's disease.
Indexed as
Identifiers
41191323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.